Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of thiotepa-containing regimens in primary central nervous system lymphoma
ChiCTR2200055554Phase 2Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thiotepa in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Objective response rate. Started Apr 2022; status: recruiting.
02
Drugs
thiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200055554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055554.